Treatment related factors associated with the risk of breast radio-induced-sarcoma. (June 2022)

• Record Type: Journal Article
• Authors: Mirjolet, Céline; Diallo, Ibrahima; Bertaut, Aurélie; Veres, Cristina; Sargos, Paul; Helfre, Sylvie; Sunyach, Marie-Pierre; Truc, Gilles; Le Pechoux, Cécile; Paumier, Amaury; Ducassou, Anne; Jolnerovski, Maria; Thariat, Juliette; Lapeyre, Michel; Cordoba, Abel; Mahé, Marc-André; Maingon, Philippe
• Is Part Of: Radiotherapy and oncology. Volume 171(2022)
• Page Start: 14
• Page End: 21
• Publication Date: 2022-06
• Subjects: Radiation induced sarcoma (RIS) -- Dose distribution -- Anthropomorphic phantom -- Late effect; Oncology -- Periodicals; Radiotherapy -- Periodicals; Tumors -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- radiotherapy -- Periodicals; Radiotherapy -- Periodicals; Radiothérapie -- Périodiques; Cancérologie -- Périodiques; Tumeurs -- Périodiques; Electronic journals; 616.9940642
• DOI: 10.1016/j.radonc.2022.04.004
• Languages: English
• ISSNs: 0167-8140

Abstract

Highlights: The RIS development area was almost always in full beam. Reassuringly, new RT techniques such as VMAT should not have an impact on the incidence of RIS. Patients developing RIS in low dose areas may have an individual predisposition. Abstract: Background and purpose: The Radiation Induced Sarcoma (RIS) is a rare but serious adverse event following radiotherapy (RT). Current RT techniques are more precise, but irradiate a larger volume at a low dose. This study aimed to describe radiation characteristics in a large series of patients suffering from RIS. Materials and methods: Patient-representative voxel-based anthropomorphic phantoms were used to reconstruct patient-specific RT fields for 125 patients diagnosed with RIS after primary breast cancer. For each patient, the location of the RIS onset site was determined and transferred onto the phantom as a contour. Using a treatment planning system (TPS), the dose distribution on the RIS in the phantom was calculated. Results: The mean dose (Dmean) received in the area where RIS subsequently developed was 47.8 ± 11.6 Gy. The median dose in the zones where RIS later developed ranged from 11 Gy to 58.8 Gy. The median time from RT to RIS development was 8 years (range 2–32 years). Analysis for predictors of time to radiation-induced sarcoma development highlighted a significant impact of age of patient during the RT whereas in multivariable analysis chemotherapy and hormonotherapy for primary breast cancer were not associated with a significant difference in time to diagnosis of RIS. Conclusions: This study highlights that the dose received by the tissue in which the RIS developed was almost 47 Gy. These results are encouraging for the use of new RT techniques increasing volumes receiving low doses, without fear of an excess of RIS over the next 10 years.